Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

In a challenging market environment, Immunic, Inc. (NASDAQ:IMUX) stock has recorded a new 52-week low, dipping to $0.92. The biopharmaceutical company, which focuses on developing treatments for ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Research analysts at William Blair issued their FY2025 earnings per share (EPS) estimates for shares of Immunic in a research note issued to investors on Monday, March 24th. William Blair analyst M.

So should Immunic (NASDAQ:IMUX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

Short interest in Immunic Inc (NASDAQ:IMUX) decreased during the last reporting period, falling from 2.55M to 2.40M. This put 2.69% of the company's publicly available shares short. Short interest ...

The firm increased its portfolio allocation in IMUX by 12.46% over the last quarter. Soleus Capital Management holds 7,293K shares representing 8.10% ownership of the company. No change in the ...